ChemGenex Therapeutics

ChemGenex Therapeutics, Inc. is a biopharmaceutical company that researches, develops, and markets small molecule therapies for the treatment of cancer and infectious diseases. The company's products include Ceflatonin (homoharringtonine), which is in Phase II clinical trials with patient enrollment for chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS), and Quinamed (amonafide hydrochloride), currently undergoing Phase II clinical trials for solid tumors. ChemGenex Therapeutics utilizes chemogenomics, medical informatics, and high-throughput in vitro and in vivo drug screening systems to develop molecular therapies. The company was founded in 1999 and is headquartered in Menlo Park, California.